Yang Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yang Yang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Hongzhe Zhao
Northeast Agricultural University
2 shared publications - Jiaxuan Li
College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, China; Northeast Science Observation Station for Animal Pathogen Biology, Ministry of Agriculture and Rural Affairs, Harbin 150030, China; Heilongjiang Key Laboratory for Animal Disease Control and Pharmaceutical Development, Harbin 150030, China
2 shared publications - Rongyan Li
Heilongjiang Key Laboratory for Animal Disease Control and Pharmaceutical Development, Department of Preventive Veterinary Medicine, College of Veterinary Medicine, Northeast Agricultural University, 600 Changjiang Road, Harbin 150030, China
2 shared publications - Wen Cui
College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, China
2 shared publications - Xinyuan Qiao
Heilongjiang Key Laboratory for Animal Disease Control and Pharmaceutical Development, Department of Preventive Veterinary Medicine, College of Veterinary Medicine, Northeast Agricultural University, Harbin, China
2 shared publications - Fei Teng
Northeast Agricultural University
1 shared publication
Latest Publications
- Open Access
A High-Potency Bovine Consensus Interferon Delivered by an Oral Lactococcus lactis System Exhibits Antiviral Activity Against VSV and BEV
Interferon-alpha (IFN-α) mediates innate antiviral immunity. Although it comprises multiple subtypes, their functional divergence and application potential remain incompletely characterized. In this study, we identified 13 BoIFN-α subtypes (A1–A13) in the bovine genome through bioinformatic analysis. Prokaryotic expression and functional comparison revealed substantial differences in antiviral activity among these subtypes (up to 77.7-fold), with BoIFN-A8 being the most potent. Based on these findings, we designed a novel consensus interferon, BoIFN-Acons, by multiple sequence alignment and successfully synthesized it. When expressed in E. coli, BoIFN-Acons exhibited superior antiviral potency (2.36 × 105 U/mg), which was 16.2-fold higher than that of the most active natural subtype. To establish a safe delivery system, we integrated the codon-optimized gene into a food-grade L. lactis expression platform and achieved efficient supernatant production. In vitro assays confirmed that the recombinant BoIFN-Acons effectively suppressed replication of Vesicular stomatitis virus (VSV) and Bovine enterovirus (BEV) and significantly upregulated interferon-stimulated genes (ISGs) such as Mx1 and OAS1. Furthermore, in vivo experiments demonstrated that oral administration of the engineered L. lactis strain alleviated virus-induced clinical symptoms, reduced viral loads in major tissues, and induced upregulation of immune-related genes in the spleen, showing significant prophylactic and therapeutic efficacy. Collectively, this study systematically elucidated the functional diversity of BoIFN-α subtypes and developed a highly active consensus interferon delivered via an oral lactic acid bacteria system, providing a new strategy for the eco-friendly control of animal viral diseases.
Open AccessA High-Potency Bovine Consensus Interferon Delivered by an Oral Lactococcus lactis System Exhibits Antiviral Activity Against VSV and BEV
Interferon-alpha (IFN-α) mediates innate antiviral immunity. Although it comprises multiple subtypes, their functional divergence and application potential remain incompletely characterized. In this study, we identified 13 BoIFN-α subtypes (A1–A13) in the bovine genome through bioinformatic analysis. Prokaryotic expression and functional comparison revealed substantial differences in antiviral activity among these subtypes (up to 77.7-fold), with BoIFN-A8 being the most potent. Based on these findings, we designed a novel consensus interferon, BoIFN-Acons, by multiple sequence alignment and successfully synthesized it. When expressed in E. coli, BoIFN-Acons exhibited superior antiviral potency (2.36 × 105 U/mg), which was 16.2-fold higher than that of the most active natural subtype. To establish a safe delivery system, we integrated the codon-optimized gene into a food-grade L. lactis expression platform and achieved efficient supernatant production. In vitro assays confirmed that the recombinant BoIFN-Acons effectively suppressed replication of Vesicular stomatitis virus (VSV) and Bovine enterovirus (BEV) and significantly upregulated interferon-stimulated genes (ISGs) such as Mx1 and OAS1. Furthermore, in vivo experiments demonstrated that oral administration of the engineered L. lactis strain alleviated virus-induced clinical symptoms, reduced viral loads in major tissues, and induced upregulation of immune-related genes in the spleen, showing significant prophylactic and therapeutic efficacy. Collectively, this study systematically elucidated the functional diversity of BoIFN-α subtypes and developed a highly active consensus interferon delivered via an oral lactic acid bacteria system, providing a new strategy for the eco-friendly control of animal viral diseases.
- Open Access
- 23 July 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (8) , 1606
Prophylactic Administration of Engineered Bacillus subtilis Expressing Mucosal Repair Factors Alleviates Pullorum Disease in Chicks
Salmonella pullorum (S. pullorum) remains a major enteric pathogen in young chicks, causing high mortality and severe economic losses in poultry production. This study evaluated a prophylactic strategy using engineered Bacillus subtilis (B. subtilis) expressing gallus trefoil factor 2 (gTFF2) and epidermal growth factor (gEGF) to protect chicks against S. pullorum infection. In vitro, gEGF significantly promoted UMNSAH/DF-1 (DF-1) cell proliferation, whereas both gTFF2 and gEGF enhanced epithelial cell migration. In vivo, oral administration of recombinant B. subtilis significantly reduced mortality from 75.0% and 66.7% in the PBS and pHT43 groups to 50%, 33.3%, and 25.0% in the gTFF2, gEGF, and gTFF2+gEGF groups, respectively. Cecal colonization of S. pullorum was reduced by 2–4 log10 CFU/g, accompanied by improved average daily gain and immune organ indices. Treatment also significantly decreased serum IL-6 levels and increased TGF-β levels (p < 0.05), indicating attenuation of the inflammatory response. Histological analysis showed significantly increased villus height (0.94–1.58-fold) and villus height-to-crypt depth ratio (1.47–3.25-fold) compared with the infected controls, together with markedly alleviated hepatic and intestinal lesions. The combined administration of gTFF2- and gEGF-expressing strains consistently exhibited the greatest protective efficacy. Collectively, these findings demonstrate that engineered probiotic-mediated delivery of mucosal repair factors represents a promising antibiotic-alternative strategy for preventing pullorum disease and improving intestinal health in poultry production.
- 23 July 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (8) , 1606
Open AccessProphylactic Administration of Engineered Bacillus subtilis Expressing Mucosal Repair Factors Alleviates Pullorum Disease in Chicks
Salmonella pullorum (S. pullorum) remains a major enteric pathogen in young chicks, causing high mortality and severe economic losses in poultry production. This study evaluated a prophylactic strategy using engineered Bacillus subtilis (B. subtilis) expressing gallus trefoil factor 2 (gTFF2) and epidermal growth factor (gEGF) to protect chicks against S. pullorum infection. In vitro, gEGF significantly promoted UMNSAH/DF-1 (DF-1) cell proliferation, whereas both gTFF2 and gEGF enhanced epithelial cell migration. In vivo, oral administration of recombinant B. subtilis significantly reduced mortality from 75.0% and 66.7% in the PBS and pHT43 groups to 50%, 33.3%, and 25.0% in the gTFF2, gEGF, and gTFF2+gEGF groups, respectively. Cecal colonization of S. pullorum was reduced by 2–4 log10 CFU/g, accompanied by improved average daily gain and immune organ indices. Treatment also significantly decreased serum IL-6 levels and increased TGF-β levels (p < 0.05), indicating attenuation of the inflammatory response. Histological analysis showed significantly increased villus height (0.94–1.58-fold) and villus height-to-crypt depth ratio (1.47–3.25-fold) compared with the infected controls, together with markedly alleviated hepatic and intestinal lesions. The combined administration of gTFF2- and gEGF-expressing strains consistently exhibited the greatest protective efficacy. Collectively, these findings demonstrate that engineered probiotic-mediated delivery of mucosal repair factors represents a promising antibiotic-alternative strategy for preventing pullorum disease and improving intestinal health in poultry production.